MDGL Projected Dividend Yield
Madrigal Pharmaceuticals Inc ( NASDAQ : MDGL )Madrigal Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Co.'s primary product candidate, resmetirom, is being developed as a once-daily oral pill to treat several disease states, including non-alcoholic steatohepatitis, or NASH. Co. has initiated MAESTRO-NASH, a Phase 3 trial in NASH with its once daily, oral thyroid hormone receptor beta selective agonist, resmetirom. Co. has opened for enrollment MAESTRO-NAFLD-1, a Phase 3 clinical study of patients with biopsy-confirmed or presumed NASH recruited from sites in the U.S. 20 YEAR PERFORMANCE RESULTS |
MDGL Dividend History Detail MDGL Dividend News MDGL Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |